Investment Rating - The investment rating for the company is "Outperform the Market" [5] Core Insights - The company is expected to achieve significant growth in both profit and value by the end of 2025, with projected revenue of 615.68 billion yuan, a year-on-year increase of 16.5%, and a net profit attributable to shareholders of 154.08 billion yuan, reflecting a 44.1% growth [1] - The New Business Value (NBV) for 2025 is projected to be 45.75 billion yuan, a substantial increase of 35.7%, marking the highest growth rate since 2017 [2] - The company has significantly increased its equity asset allocation, with the proportion of stocks and funds rising from 12.18% at the end of 2024 to 16.89% by the end of 2025, contributing to a total investment return of 6.09%, up 59 basis points year-on-year [3] Financial Projections - The company forecasts revenue growth from 528.57 billion yuan in 2024 to 615.68 billion yuan in 2025, with a projected net profit increase from 106.94 billion yuan to 154.08 billion yuan during the same period [4] - The diluted earnings per share (EPS) are expected to rise from 3.78 yuan in 2024 to 5.45 yuan in 2025, with further increases projected for 2026 and 2027 [4] - The price-to-earnings (P/E) ratio is projected to decrease from 10.39 in 2024 to 7.21 in 2025, indicating improved valuation metrics [6]

Investment Rating - The investment rating for the company is "Buy" [6][5] Core Insights - The company reported a net profit of RMB 154.1 billion for 2025, representing a year-on-year growth of 44%, although this was below previous expectations of RMB 171.8 billion due to investment volatility [1] - The total investment return rate for 2025 reached 6.09%, an increase of 59 basis points year-on-year, primarily driven by strong equity market performance [1] - The New Business Value (NBV) grew by 35.7% year-on-year in 2025, with individual insurance and other channels increasing by 25.5% and 169.3% respectively, mainly driven by the bancassurance channel [1][2] - The company experienced a slight loss in Q4 2025, attributed to investment volatility and increased asset impairments [1] - The company maintained a dividend per share (DPS) of RMB 0.856, a 32% increase year-on-year, with a dividend payout ratio of 16%, slightly down from the previous year [1] Summary by Sections Financial Performance - The company achieved a net profit of RMB 154.1 billion in 2025, with a year-on-year increase of 44% [1] - The total investment income for 2025 was RMB 383.7 billion, reflecting a 29.01% increase year-on-year [10] - The NBV for 2025 was RMB 45.8 billion, with a year-on-year growth of 35.7% [2][10] Investment and Asset Allocation - The company significantly increased its allocation to secondary equity assets, with the proportion of stocks and funds rising by 4.7 percentage points to 16.9% [4] - The company’s investment performance improved, with a 30% increase in investment income driven by rising equity asset prices [4] Future Projections - The EPS estimates for 2026, 2027, and 2028 have been adjusted to RMB 3.89, RMB 4.14, and RMB 4.55 respectively, reflecting a downward revision of 7% and 13% for 2026 and 2027 [5] - The target price for the company's A/H shares has been raised to RMB 53 and HKD 32, respectively [5]

Investment Rating - The industry investment rating is "Outperform the Market" [4] Core Insights - China Life's 2025 annual report shows total premiums of 729.887 billion yuan (YoY +8.7%), net profit attributable to shareholders of 154.078 billion yuan (YoY +44.1%), and net assets of 608.393 billion yuan (up 16.7% from the end of the previous year) [2] - The company declared a total cash dividend of 24.195 billion yuan, accounting for approximately 15.7% of net profit attributable to shareholders [2] - The report highlights a significant increase in new business value (NBV) by 35.7% YoY, reaching approximately 45.8 billion yuan, reflecting strong demand for savings among residents [3] Summary by Sections Life Insurance - The transition to floating income-type business is accelerating, with a new single premium of 234.1 billion yuan (YoY +9.3%) and first-year regular premium of 116.2 billion yuan (YoY -2.4%) [3] - The proportion of floating income-type business in first-year regular premiums is nearly 50% [3] - The individual insurance channel has seen a stable increase, with first-year regular premiums of 89.2 billion yuan (YoY -11.0%) and NBV of 39.3 billion yuan (YoY +25.5%) [3] Investment - The company dynamically optimizes asset allocation, increasing equity investments, with total investment income of 387.694 billion yuan (YoY +25.8%) and an investment return rate of 6.09% (YoY +0.59%) [3] - The equity investment ratio reached 16.89% (YoY +4.71 percentage points) [3] Investment Recommendations - The report suggests that the life insurance industry is expected to maintain robust growth in new business and NBV in 2026, with a focus on stable development of companies like China Pacific Insurance and China Life [3]

Market Overview - The Hong Kong stock market opened lower on March 26, with the Hang Seng Index down 0.27% at 25,267.16 points, the Hang Seng Tech Index down 0.68% at 4,889.55 points, and the National Enterprises Index down 0.41% at 8,547.82 points. The Red Chip Index, however, rose by 0.34% to 4,226.15 points [1] Company Performance - China Life (02628.HK) reported a total revenue of 616.065 billion yuan for 2025, a year-on-year increase of 16.5%, and a net profit of 154.078 billion yuan, up 44.1% [2] - Kuaishou (01024.HK) projected a revenue of 142.776 billion yuan for 2025, reflecting a 12.5% year-on-year growth, with a net profit of 18.617 billion yuan, increasing by 21.4% [3] - Guming (01364.HK) expects a revenue of 12.914 billion yuan for 2025, a significant increase of 46.9%, and a profit of 3.109 billion yuan, up 110.3% [4] - Kingsoft (03888.HK) anticipates a revenue of 9.683 billion yuan for 2025, a decrease of 6%, while net profit is expected to rise by 29% to 2.004 billion yuan [5] - Qianfeng Holdings (02285.HK) forecasts a revenue of approximately 1.628 billion USD for 2025, down 8.2%, with a net profit of approximately 97.76 million USD, down 13.2% [6] - IGG (00799.HK) expects a revenue of 5.497 billion HKD for 2025, a decrease of 4.19%, with net profit remaining stable at 580 million HKD [7] - Binhai Services (03316.HK) projects a revenue of 4.101 billion yuan for 2025, an increase of 14.1%, and a net profit of 596 million yuan, up 9% [8] - ZhiHu (02390.HK) anticipates a revenue of 2.749 billion yuan for 2025, with a gross margin of 59.9%, and an adjusted net profit of 37.9 million yuan, indicating a turnaround [8] Sector Insights - The semiconductor sector, along with lithium battery and new consumption concepts, experienced declines, with CATL opening down nearly 3% [1] - The biopharmaceutical sector showed activity, with companies like Lepu Biotech seeing significant revenue growth [1] - Insurance stocks, particularly China Ping An, saw a substantial increase of over 5% [1] Analyst Opinions - Goldman Sachs noted a rise in international investor interest in Chinese stocks, with only about 10% of surveyed clients considering the Chinese stock market "non-investable," a significant improvement from 40% two years ago [14] - CITIC Securities suggested that the current market sentiment has been sufficiently impacted by geopolitical conflicts, and if tensions do not escalate further, the market could quickly return to a trend driven by domestic economic policies and liquidity [14] - Zhongyuan Securities emphasized the importance of monitoring macroeconomic data, overseas liquidity changes, and policy developments, recommending a focus on sectors like non-ferrous metals, consumer electronics, communication equipment, and semiconductors for investment opportunities [14]

Group 1 - SpaceX is preparing for its largest IPO, planning to submit confidential documents to regulators soon, with a target valuation of $1.75 trillion and expected fundraising of $50 billion to $75 billion [2] - OpenAI will shut down its Sora video generation service and terminate its partnership with Disney to streamline its AI product line [3] - Pop Mart's revenue for 2025 is projected to reach 37.12 billion yuan, a year-on-year increase of 184.7%, with adjusted net profit expected to be 13.08 billion yuan, up 284.5% [3] - Pinduoduo's Q4 2025 revenue is expected to be 123.91 billion yuan, a 12% year-on-year increase, while adjusted net profit is projected to decline by 12% [4] - Meta faces a lawsuit regarding social media addiction, with a ruling requiring it to pay 70% of damages, and plans to lay off hundreds of employees [4] Group 2 - China Life achieved a revenue of 615.68 billion yuan in 2025, a 16.5% year-on-year increase, with a net profit of 154.08 billion yuan, up 44.1% [6] - China Eastern Airlines signed a purchase agreement for 101 A320NEO aircraft with a catalog price of approximately $15.802 billion [7] - Zijin Mining reported a 62% increase in net profit for 2025, marking a historical high [7] - Alibaba Health partnered with Novartis to provide integrated services for chronic spontaneous urticaria [7] - BASF announced price increases for its commodity amines portfolio in Europe, with increases potentially reaching 30% due to rising costs from geopolitical tensions [16]

Annual Results 26 March 2026 | Beijing • Hong Kong FORWARD LOOKING STATEMENT Certain statements contained in this presentation may be viewed as "forward-looking statements". These forward-looking statements state our intentions, beliefs, expectations or predictions for the future; and in some cases, we use words such as "believe", "intend", "anticipate", "estimate", "project", "forecast", "plan", "potential", "will", "may", "should" and "expect" and similar expressions to identify forward-looking statements ...

Investment Rating - The report maintains a "Buy" rating for both A-shares and H-shares of the company [3] Core Views - The company achieved a net profit of 154.08 billion yuan in 2025, representing a year-on-year increase of 44.1%. The new business value (NBV) was 45.75 billion yuan, up 35.7% year-on-year, with a proposed dividend per share of 0.856 yuan, an increase of 31.7% [1][9] - The company’s investment assets reached 7.42 trillion yuan by the end of 2025, showing a growth of 12.3% compared to the end of 2024. The proportion of core secondary equity assets has significantly increased [9] - The company’s total investment return rate for 2025 was 6.09%, an increase of 0.59 percentage points year-on-year, with net investment income of 193.8 billion yuan, a decrease of 1.0% year-on-year [9] Financial Forecasts - For 2026, the company is expected to achieve a net profit of 119.84 billion yuan, a decrease of 22.2% year-on-year, followed by a recovery with projected profits of 132.32 billion yuan in 2027 and 144.54 billion yuan in 2028 [2][10] - The estimated earnings per share (EPS) for 2026 is 4.2 yuan, with a projected increase to 4.7 yuan in 2027 and 5.1 yuan in 2028 [2] - The estimated enterprise value per share (EVPS) is projected to be 54.3 yuan in 2026, increasing to 56.6 yuan in 2027 and 58.8 yuan in 2028 [2] Business Performance - The company’s NBV from individual insurance and bancassurance channels reached 39.30 billion yuan and 6.45 billion yuan respectively, with year-on-year growth of 25.5% and 169.3% [9] - The new single premium income increased by 9.3% year-on-year to 234.08 billion yuan, with the NBV margin rising by 3.8 percentage points to 19.5% [9] - The company’s first-year regular premium income from floating income products accounted for nearly 50% of the total, indicating a successful transformation in product offerings [9]

1. 提名薪酬委員會是公司董事會專門委員會，負責檢討董事會架構、人數和組 成，擬定董事、高級管理人員的選擇標準和程序，對董事、高級管理人員人選 及其任職資格進行遴選、審核，制定董事、高級管理人員的考核標準、薪酬政 策、培訓計劃等，以及檢討董事會及公司多元化政策。 2. 提名薪酬委員會由 3-7 名不在公司擔任高級管理人員的董事組成，其中獨立董 事應當過半數並擔任主席（主任委員）。 3. 提名薪酬委員會就下列事項向董事會提出建議： (a) 提名或者任免董事，聘任或者解聘高級管理人員； (b) 董事、高級管理人員的考核標準及結果； (c) 董事、高級管理人員的薪酬，包括研究及審查董事及高級管理人員的薪 酬政策、方案及架構，就設立正規而具透明度的程序制訂薪酬政策，根 據企業方針及目標檢討和批准董事及高級管理人員的薪酬建議，同時確 保任何董事及其聯繫人不得參與釐定其本身的薪酬； (d) 根據董事會的授權，釐定執行董事及高級管理人員的薪酬待遇，薪酬包 括非金錢利益、退休金權利及賠償金額（包括喪失或終止職務或委任的 賠償），提名薪酬委員會應考慮的因素包括同類公司支付的薪酬、須付 出的時間及職責以及集團內其他職位的僱用條件 ...

EF001 EF001 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 中國人壽保險股份有限公司 | | 股份代號 | 02628 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年12月31日止年度的末期股息 | | 公告日期 | 2026年3月25日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 股 0.618 RMB | | 股東批准日期 | 2026年6月25日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | HKD， 金額有待公佈 | | 匯率 | 有待公佈 | | ...

中國人壽保險股份有限公司董事會 提名薪酬委員會職權範圍 1. 提名薪酬委員會是公司董事會專門委員會，負責檢討董事會架構、人數和組 成，擬定董事、高級管理人員的選擇標準和程序，對董事、高級管理人員人選 及其任職資格進行遴選、審核，制定董事、高級管理人員的考核標準、薪酬政 策、培訓計劃等，以及檢討董事會及公司多元化政策。 2. 提名薪酬委員會由 3-7 名不在公司擔任高級管理人員的董事組成，其中獨立董 事應當過半數並擔任主席（主任委員）。 3. 提名薪酬委員會就下列事項向董事會提出建議： (a) 提名或者任免董事，聘任或者解聘高級管理人員； (b) 董事、高級管理人員的考核標準及結果； (c) 董事、高級管理人員的薪酬，包括研究及審查董事及高級管理人員的薪 酬政策、方案及架構，就設立正規而具透明度的程序制訂薪酬政策，根 據企業方針及目標檢討和批准董事及高級管理人員的薪酬建議，同時確 保任何董事及其聯繫人不得參與釐定其本身的薪酬； (d) 根據董事會的授權，釐定執行董事及高級管理人員的薪酬待遇，薪酬包 括非金錢利益、退休金權利及賠償金額（包括喪失或終止職務或委任的 賠償），提名薪酬委員會應考慮的因素包括同類公司支付 ...